We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Almac extends Site-specific PEGylation Technology to single domain antibodies
Product News

Almac extends Site-specific PEGylation Technology to single domain antibodies

Almac extends Site-specific PEGylation Technology to single domain antibodies
Product News

Almac extends Site-specific PEGylation Technology to single domain antibodies


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Almac extends Site-specific PEGylation Technology to single domain antibodies"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

In exemplifying the site specific PEGylation technology with single domain antibodies and interferons, Almac has demonstrated that therapeutically important complex biological proteins can be engineered to offer viable candidates for development as therapeutic agents.

Existing PEGylation technologies produce products which are PEGylated at multiple sites in an uncontrolled manner. Inevitably, this results in heterogeneous population of PEGylated molecules and a net decrease in potency compared to the un-PEGylated analogue. The Almac approach allows the specific PEGylation site to be selected and controlled and generates a homogeneous PEGylated product. The outcome, compared to existing PEGylation techniques, is improved efficacy, which leads to lower dose levels and consequently lower cost of goods; whilst still providing improved ADME profile due to the addition of the PEG moiety.

Commenting on the development of Almac’s site specific ligation technology,  Almac Sciences’ President and Managing Director, Stephen Barr, commented: “The application of our unique ligation technology to the PEGylation of single domain antibody fragments, further demonstrates the benefit of Almac’s state of the art peptide and protein engineering techniques for the improvement of drug products.’

Advertisement